Agendia Inc. USA

https://www.agendia.com

Agendia is an international molecular diagnostic company, focused on the discovery and development of tools to improve the quality of life for cancer patients, by providing healthcare professionals with critical information that enables personalized treatment. Agendia's Symphony™ suite of breast cancer products is based on genomic analysis of an individual patient's tumor biology, providing unprecedented insight for complex treatment decisions. Symphony includes MammaPrint, the first and only FDA-cleared breast cancer recurrence assay, as well as BluePrint, a molecular subtyping assay, TargetPrint®, an ER/PR/HER2 expression assay, and TheraPrint®, a therapy selection assay. Together, these tests help physicians determine a patient's individual risk for metastasis, which patients will benefit from chemo or hormonal therapy, and which patients do not require these treatments and can instead be treated with other less arduous and costly methods. *

	Start	2014-04-30 existent
	Group	Agendia (Group)
	Industry	cancer test, molecular diagnostics
	Industry 2	MammaPrint® breast cancer test
	Person	Macdonald, David (Agendia 201110– CEO before before COO since 201104 before Quest Diagnostics et al)
	Person 2	Fredenberg, Glen (Agendia 201207– CFO before CFO at Clarient + CFO at US Labs

	Region	Irvine, CA
	Country	United States (USA)
	Street	22 Morgan
	City	92618 Irvine, CA
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for »About Section«:

		Record changed: 2023-07-10